Enzymatica AB: Updated time plan for the acquisition of Zymetech and the rights issue
17 March 2016 - 9:14PM
This press release may not be
published or distributed, directly or indirectly, in or into the
United States, Australia, Japan, Canada, Hong Kong, New Zealand,
Singapore or South Africa or any other jurisdiction where such
action is subject to legal restrictions.
Press Release
Lund on 17 March 2016
The estimated date for the
completion of Enzymatica AB (publ)'s (the "Company") acquisition of
Zymetech ehf. is 1 April 2016 as the Company and the sellers
estimate that the conditions for completion will be satisfied
during March 2016. The time plan for the rights issue means inter
alia that an extra general meeting will be held on 14 April 2016
according to notice that has been published and that the last day
of trading including subscription rights is 15 April 2016.
The first day of trading excluding subscription rights is 18 April
2016.
On 28 January 2016, the Company's acquisition of
the Icelandic company Zymetech ehf was announced. The transaction
was approved by the extra general meeting in the Company on 15
February 2016. The Company and the sellers are now planning to
complete the transaction on 1 April 2016 as the remaining
conditions for completion are estimated to be satisfied during
March 2016, including the obtainment of necessary governmental
approvals.
Time plan
1
April |
Completion of the Zymetech acquisition |
14
April |
Extraordinary shareholders' meeting |
15
April |
Last day
of trading inclusive subscription rights |
18
April |
First day
of trading exclusive subscription rights |
19
April |
Record
date for participation in the rights issue |
20
April |
Estimated
date for publication of the prospectus |
21 April
- 3 May |
Trading
in subscription rights |
21 April
- 6 May |
Subscription period |
11
May |
Estimated
day for announcement of outcome of the rights issue |
Further details on participation in the rights
issue is set out in the notice that has been published and coming
prospectus.
For
more information, contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser
Bankaktiebolag.
Important
information
The information in this press release does not
contain or constitute an offer to acquire, subscribe or otherwise
trade in shares, subscription rights or other securities in
Enzymatica AB (publ). Any invitation to the persons concerned to
subscribe for shares in Enzymatica AB (publ) will only be made
through the prospectus that Enzymatica AB (publ) estimates to
publish on or about 20 April 2016.
This press release may not be
published or distributed, directly or indirectly in or into the
United States, Australia, Japan, Canada, Hong Kong, New Zealand,
Singapore or South Africa or any other jurisdiction where such
action is wholly or partially subject to legal restrictions or
where such action would require additional prospectuses,
registrations or other actions in addition to what follows from
Swedish law. Nor may the information in this press release be
forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or would require such requirements.
Failure to comply with this instruction may result in a violation
of applicable securities laws.
No subscription rights, interim
shares or new shares have been registered, and will not be
registered, under the United States Securities Act of 1933
("Securities Act") or securities legislation in any other state or
other jurisdiction in the United States and may not be offered,
subscribed, sold or transferred, directly or indirectly within the
United States, other than pursuant to an exemption from the
registration requirements of the Securities Act and in accordance
with securities laws in relevant state or other jurisdiction in the
United States.
This press release may contain
forward-looking statements which reflect Enzymatica AB (publ):s
current view on future events and financial and operational
development. Words such as "intend", "expect", "anticipate", "may",
"believe", "plan", "estimate" and other expressions which imply
indications or predictions of future development or trends, and
which are not based on historical facts, are intended to identify
forward-looking statements. Forward-looking statements inherently
involve both known and unknown risks and uncertainties because they
depend on future events and circumstances. Forward-looking
statements do not guarantee future results or development and the
real outcome could differ materially from the forward-looking
statements.
Press Release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#1995550
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024